eFFECTOR drops MNK inhibitor after lung cancer flop

04 Apr 2024
firstwordpharma.com
Clinical ResultPhase 2ADCPhase 1
eFFECTOR Therapeutics said Thursday it will halt development of tomivosertib in lung cancer after the MNK inhibitor failed to significantly improve survival. Shares of the selective translation regulator inhibitor (STRI) developer plummeted 82%.
The 180-person Phase II KICKSTART trial randomised patients with PD-L1-expressing non-small-cell lung cancer (NSCLC)PD-L1-expressing non-small-cell lung cancer (NSCLC) to receive either tomivosertib plus Merck & Co.’s Keytruda (pembrolizumab) as a frontline treatment, or the anti-PD-1 antibody plus placebo.
The tomivosertib arm achieved a median progression free survival (PFS) of 13 weeks, which was not statistically significant compared with the PFS of 11.7 weeks seen by the comparator arm.
Additionally, eFFECTOR said that there is “no trend favouring tomivosertib” in regards to overall survival (OS). The oral small molecule also had a worse safety profile, with 67% Grade 3 or higher treatment emergent adverse events compared with 37% in the Keytruda plus placebo group.
While chief executive Steve Worland confirmed that “tomivosertib won’t be moving forward in frontline NSCLC,” he added that an investigator-sponsored trial in acute myeloid leukaemia (AML) “will continue unchanged.”
Moving forward, eFFECTOR will be focusing its development efforts on zotatifin, a small molecule inhibitor of eIF4A that’s in Phase II testing to treat ER-positive breast cancer and KRAS-mutant NSCLC in combination with Faslodex (fulvestrant) and Verzenio (abemaciclib). A data readout is expected next half.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.